https://ph-ksp.com/whats-new-on-the-ph-knowledge-sharing-platform-october-2026/ 2026-10-29T17:12:17Z PULMONARY HYPERTENSION en What's new on the Pulmonary Hypertension Knowledge Sharing Platform - October 2026 2026-10-29T17:09:15Z Blog https://ph-ksp.com/extension-studies-in-treprostinil-palmitil-inhalation-powder-tpip-show-promise-in-pulmonary-arterial-hypertension-pah-and-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild/ 2026-10-29T09:51:01Z PULMONARY HYPERTENSION en Extension Studies in Treprostinil Palmitil Inhalation Powder (TPIP) Show Promise in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), American Journal of Managed Care, October 20, 2026 2026-10-29T09:50:58Z Blog https://ph-ksp.com/five-new-pep-talks-now-online-in-the-dedicated-section-of-this-website/ 2026-10-29T20:12:09Z PULMONARY HYPERTENSION en Five new PEP Talks now online in the dedicated section of this website 2026-10-28T17:22:00Z Blog https://ph-ksp.com/update-on-investigational-formulation-of-inhaled-rapamycin-mtor-inhibitor-for-multiple-pulmonary-diseases-including-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-and-bro/ 2026-10-27T22:03:50Z PULMONARY HYPERTENSION en Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026 2026-10-27T21:56:55Z Blog https://ph-ksp.com/pulmonary-arterial-hypertension-pah-in-the-era-of-obesity-navigating-phenotypes-of-pulmonary-hypertension-expert-review-of-respiratory-medicine-october-22-2026/ 2026-10-27T21:48:33Z PULMONARY HYPERTENSION en Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026 2026-10-27T21:38:57Z Blog https://ph-ksp.com/first-report-of-real-world-utilization-of-an-activin-signaling-inhibitor-in-patients-with-severe-pulmonary-arterial-hypertension-in-the-middle-east-pulmonary-circulation-ph-riseoctober-22-2026/ 2026-10-27T21:31:16Z PULMONARY HYPERTENSION en First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026 2026-10-27T21:30:54Z Blog